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ematopoietic  stem  cell  mobilization  for
utologous transplantation  in multiple  myeloma
atients previously  exposed  to cyclophosphamide,
halidomide, and  dexamethasone:  is
ranulocyte-colony stimulating  factor  alone
nough?fonso Celso Vigorito ∗
ulo, Bniversidade Estadual de Campinas (UNICAMP), Campinas, São Pa
he paradigm for multiple myeloma (MM)  therapy has evolved
arkedly in the past decade with the introduction of numer-
us new drugs and improved patient outcomes.1
Autologous hematopoietic stem cell transplantation
aHSCT) is widely used as part of ﬁrst line therapy in the
reatment of transplant-eligible patients with MM.2 In these
atients, hematopoietic stem cell (HSC) mobilization for
HSCT has commonly been performed using cyclophos-
hamide plus granulocyte-colony stimulating factor (G-CSF)
r G-CSF alone.3,4 However, the induction regimens should
ot increase the mobilization failure risk. This concern has
een especially pertinent to patients previously exposed to
yclophosphamide or lenalidomide during induction, as these
rugs appear to hamper HSC mobilization. In the article that
ccompanies this comment, Crusoe et al. demonstrate the
easibility of using G-CSF alone to mobilize progenitor cells in
M patients induced with a cyclophosphamide, thalidomide
nd dexamethasone regimen.5 The number of CD34+ cells
obilized was assessed after using G-CSF with or withoutyclophosphamide.
The retrospective study of Crusoe et al. included eighty-
ight MM patients who underwent aHSCT at two Brazilian
enters.5 Collection of >2.0 × 106 CD34+ cells/kg was consid-
red sufﬁcient. The group that received cyclophosphamide
DOI of original article: http://dx.doi.org/10.1016/j.bjhh.2016.06.004.
 See paper by Crusoe et al. in Rev Bras Hematol Hemoter. 2016;38(4):
∗ Correspondence to: Hemocentro de Campinas, Rua Carlos Chagas, 480
E-mail address: afonso@unicamp.br
ttp://dx.doi.org/10.1016/j.bjhh.2016.07.006
516-8484/© 2016 Associac¸a˜o Brasileira de Hematologia, Hemoterapia
pen  access article under the CC BY-NC-ND license (http://creativecomrazil
collected a higher median number of progenitor cells [3.8
(range: 3.1–4.4) vs. 3.2 (range: 2.3–3.8) – p-value = 0.008]. How-
ever, the cyclophosphamide used in mobilization did not show
advantages in terms of mobilization, or improved response or
survival.
Indeed, we  have to consider that cyclophosphamide used
for mobilization may have some disadvantages, such as rais-
ing the cost of the procedure due to hospitalization, higher tox-
icity as patients treated with cyclophosphamide require more
time for engraftment of platelets and neutrophils, and poten-
tially a higher incidence of post-transplant infections. Elimi-
nating cyclophosphamide from the mobilization regimen has
improved patient convenience and has decreased the duration
of mobilization treatment by approximately nine days.6
We  might also argue that the higher number of progeni-
tor cells collected with cyclophosphamide plus G-CSF would
enable the storage of more  HSC for a second salvage trans-
plant. However, the utilization of stored autologous HSC to
support a second aHSCT in MM patients in the era of novel
agent therapies has been addressed. Data from Seattle showed302–309.
, 13083 878 Campinas, SP, Brazil.
that of 726 patients who had residual HSC in storage after their
ﬁrst aHSCT, only 135 patients underwent a second aHSCT.7
The percentage of patients receiving a second aHSCT has
declined over time. The resources required to collect and store
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to  support second autologous transplantation in multiple282  rev bras hematol hem
unused HSC added up to 336 extra patient days of apheresis
and 41,587 extra patient months of cryopreservation, trans-
lating into a higher average cost per patient. The authors
concluded that a reconsideration of conventional HSC collec-
tion and storage practices would save signiﬁcant cost for the
majority of MM patients who never undergo a second aHSCT.6
We  do not know whether the results from Seattle might be
translated to the reality of Brazilian patients treated within
the Brazilian National Health System (SUS) that, in some cen-
ters, precludes the use of novel and more  effective agents that
would lead to better responses before and after aHSCT.
In conclusion, the study by Crusoe et al. showed that sufﬁ-
cient progenitor cells can be mobilized to perform at least one
aHSCT with the use of G-CSF alone in patients induced using
the cyclophosphamide, thalidomide and dexamethasone pro-
tocol. This strengthens the current study as it makes a valu-
able judgment regarding the limitations of performing aHSCT
in Brazil and the need to cut costs. The questions addressed
here will have a practical impact on the clinical practice.
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